|
Through the experience and extensive biopharmaceutical network of Bradmer Pharmaceutical’s leadership team, the Company is afforded the opportunity to examine many technologies for licensing and development.
The Company’s first product candidate is the result of an exclusive worldwide license with Duke University related to the innovations of two of its pioneers working in the field of brain cancer, Dr. Darell Bigner and Dr. Michael Zalutsky.
|
